Atopic Dermatitis/Skin Diseases

Top Story

Novel hereditary angioedema therapy reduces attacks, treatment-related costs

Novel hereditary angioedema therapy reduces attacks, treatment-related costs
November 10, 2017

BOSTON — A C1-esterase inhibitor (human) delivered subcutaneously for the treatment of long-term prophylaxis associated with hereditary angioedema decreased attacks by 90% compared with therapy administered intravenously, according to findings presented at the ACAAI Annual Scientific Meeting.

Additionally, the researchers determined that total attack-related drug and other medical costs were reduced by 89% over the span of 1 year in a patient treated with C1-esterase inhibitor subcutaneous (human) (Haegarda, CSL Behring) compared with intravenous treatment.

Meeting NewsVideo

VIDEO: New treatment developments on the horizon for acute hereditary angioedema

October 28, 2017
BOSTON — The landscape of hereditary angioedema and how it is diagnosed, assessed and treated has been ever-evolving and will continue to change as new treatment…
Meeting News

Pediatric eczema linked to severe asthma-related hospitalization

October 27, 2017
BOSTON — Although total immunoglobulin E levels were unrelated to severity of hospital stay, children experience increasingly intense hospital courses if they have…

ACAAI annual meeting to showcase new discoveries, treatments

October 6, 2017 will present live coverage of the 75th American Academy of Allergy, Asthma and Immunology annual meeting from Boston beginning Oct. 26 through Oct…
More Headlines »